It is also unknown how much of resistance of endogenous signaling contributes to the heterogeneity observed in metabolic disease and the variable patient responses to pharmacological treatments including DPP4 inhibitors, GLP-1R agonists and bariatric surgery. Here, GLP1R is linked to Other metabolic disease.